Kelun-Biotech's NDA Approval for TROP2-ADC Treatment
Kelun-Biotech has reached an important milestone with the acceptance of its new drug application (NDA) for sacituzumab tirumotecan (sac-TMT), also known as SKB264, by the National Medical Products Administration (NMPA). This application specifically addresses the treatment needs of adult patients suffering from epidermal growth factor receptor (EGFR)-mutant locally advanced or metastatic non-small cell lung cancer (NSCLC). These patients typically experience disease progression following the use of EGFR-tyrosine kinase inhibitor (TKI) therapy.
Details of the OptiTROP-Lung04 Study
The NDA acceptance is grounded on the promising results from the pivotal phase III OptiTROP-Lung04 trial, which was designed to explore the efficacy and safety of sac-TMT in comparison to standard treatments involving pemetrexed and platinum-based chemotherapy. In this randomized, multi-center study, sac-TMT monotherapy has shown a statistically significant improvement in progression-free survival (PFS) as assessed by a blinded independent review committee. Additionally, the safety profile of sac-TMT remains manageable, with no unforeseen safety signals reported.
NDA History and Future Potential
This marks the third NDA acceptance for sac-TMT by the NMPA. Earlier applications focusing on its use in triple-negative breast cancer and other NSCLC indications have also been accepted. Notably, the timeline for the latest NDA includes plans for priority review and expedited approval, reflecting the treatment's significance in oncology.
Innovative Mechanism of Action
Sac-TMT stands out as a novel human trophoblast cell-surface antigen 2 (TROP2) antibody-drug conjugate (ADC). It contains proprietary intellectual property rights that allow it to target various advanced solid tumors, including NSCLC and breast cancer among others. The unique design of sac-TMT features a new linker used to attach the active ingredient, a belotecan-derivative topoisomerase I inhibitor, which is effective in inducing cell cycle arrest and apoptosis in tumor cells.
Collaborations and Global Outreach
In a strategic move to enhance the drug's reach, Kelun-Biotech licensed exclusive rights to MSD (Merck & Co., Inc.) for the development and commercialization of sac-TMT outside of Greater China. This collaboration aims to leverage MSD's extensive market presence and expertise, expanding the potential impact of sac-TMT on a global scale.
Future Prospects for the Company
Dr. Micheal Ge, the CEO of Kelun-Biotech, expressed optimism regarding the future of sac-TMT in addressing unmet clinical needs. He emphasized the company’s commitment to original innovation and its resolve to improve global health outcomes through its advanced drug development initiatives. Kelun-Biotech is working hard to position itself as a key player in the oncology space.
About Kelun-Biotech
Kelun-Biotech, identified by the ticker 6990.HK, operates under the umbrella of Kelun Pharmaceutical (002422.SZ). The company is deeply engaged in the research, development, manufacturing, and commercialization of cutting-edge biological and small molecule drugs. Its focus remains on significant disease areas, especially solid tumors, as it aspires to tackle global health challenges. With a robust pipeline of over 30 innovative projects, including various candidates in clinical stages, Kelun-Biotech aims to make meaningful contributions to the medical community worldwide.
Frequently Asked Questions
What is sac-TMT?
Sac-TMT is a novel antibody-drug conjugate targeting TROP2 to treat various advanced solid tumors, including NSCLC.
What was the result of the OptiTROP-Lung04 study?
The study showed a significant improvement in progression-free survival when comparing sac-TMT to standard chemotherapy treatments.
Who licensed sac-TMT for international development?
Kelun-Biotech licensed sac-TMT to MSD (Merck & Co., Inc.) for marketing outside of Greater China.
How does sac-TMT work?
Sac-TMT utilizes topoisomerase I inhibitors that induce DNA damage in tumor cells, resulting in cell cycle arrest and subsequent cell death.
What is Kelun-Biotech's vision?
The company aims to become a leading global player in innovative drug development, focusing on original therapies and addressing unmet medical needs.
